The therapeutic efficacy of TP5 extended beyond hepatic malignancies, demonstrating substantial growth inhibition in both B16-F10 melanoma (Supplementary Figure S1A–C) and MC38 colorectal carcinoma models (Supplementary Figure S1D–F), indicating broad-spectrum antitumor activity independent of tumor types. Here, TMPO is linked to colorectal carcinoma.